Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis, under development by Anthos Therapeutics.
Mechanism of action
It is anti-factor XI antibody. The hope behind its developoment is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding. It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke. Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban.
See also
- Antibody
- Monoclonal antibody
- Immunology
References
